Changes in Beneficial Ownership · 4
Adicet Bio, Inc.
ACETNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-05
- Issuer
- Adicet Bio, Inc.
- Issuer CIK
- 0001720580
- Trading symbol
- ACET
Reporting owner 1
- Name
- Klickstein Lloyd
- Reporting owner CIK
- 0001776004
- Relationship
- Director · Officer
- Officer title
- Chief Medical Officer
- Address
- C/O ADICET BIO, INC., 131 DARTMOUTH STREET, FLOOR 3, BOSTON, MA, 02116
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 9.16 | 2026-08-05 | A · Form 4 | 18,300 | A | 0.00 | [F1] | 2036-08-04 | Common Stock | 18,300 | 18,300 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- 1/6th of the shares subject to this option shall vest and become exercisable on each of the next six (6) monthly anniversaries of August 5, 2026, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting dates.↩ 1
Signature 1
- Signed
- /s/ Nick Harvey, Attorney-in-Fact
- Date
- 2026-08-07
Company context
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing a broad pipeline of allogeneic gamma delta T cell therapies, engineered with chimeric antigen receptors (CARs), alongside differentiated in vivo CAR-T therapies with the potential to redefine treatment across autoimmune diseases, hematologic malignancies and solid tumors. For more information, please visit our website at https://www.adicetbio.com.
Current securities
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 13, 2026
- 10-Q filingNov 5, 2026
- Results of Operations and Financial ConditionNov 5, 2026
- SCHEDULE 13G/A - filed by FRANKLIN TEMPLETON INC regarding Adicet Bio, Inc.Oct 28, 2026
- Regulation FD Disclosure · Other EventsSep 28, 2026